These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34643769)

  • 1. Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Hou HA; Tzeng HE; Liu HY; Chou WC; Tien HF; Chien LN
    Ann Hematol; 2022 Jan; 101(1):109-118. PubMed ID: 34643769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Outcomes of Patients with Acute Myeloid Leukemia in Taiwan: A Nationwide Population-Based Study, 2011-2015.
    Wang CY; Huang HH; Chen HM; Hsiao FY; Ko BS
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e649-e657. PubMed ID: 33931380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: A national population-based analysis from 2001 to 2015.
    Chien LN; Tzeng HE; Liu HY; Chou WC; Tien HF; Hou HA
    J Formos Med Assoc; 2023 Jun; 122(6):505-513. PubMed ID: 36369106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
    Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML).
    Tawfik B; Pardee TS; Isom S; Sliesoraitis S; Winter A; Lawrence J; Powell BL; Klepin HD
    J Geriatr Oncol; 2016 Jan; 7(1):24-31. PubMed ID: 26527394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review.
    Bang SM; Kang KW; Song IC; Llamas C; Duan Y; Jeong JY; Lee JH
    J Korean Med Sci; 2023 Nov; 38(44):e345. PubMed ID: 37967874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.
    Reagan JL; Sullivan MR; Winer ES; Lansigan F; Cardin MS; Castillo JJ
    Leuk Res; 2015 Aug; 39(8):812-7. PubMed ID: 26045177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Effect of Using Multiagent Versus Single-agent Chemotherapy.
    Bhatt VR; Shostrom V; Holstein SA; Al-Kadhimi ZS; Maness LJ; Berger A; Armitage JO; Gundabolu K
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e239-e258. PubMed ID: 32111572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
    Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
    Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
    Konuma T; Harada K; Yamasaki S; Mizuno S; Uchida N; Takahashi S; Onizuka M; Nakamae H; Hidaka M; Fukuda T; Ohashi K; Kohno A; Matsushita A; Kanamori H; Ashida T; Kanda J; Atsuta Y; Yano S;
    Am J Hematol; 2019 Jan; 94(1):103-110. PubMed ID: 30370944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
    Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML).
    Tawfik B; Sliesoraitis S; Lyerly S; Klepin HD; Lawrence J; Isom S; Ellis LR; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee T
    Ann Hematol; 2014 Jan; 93(1):47-55. PubMed ID: 24149914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Mohty R; Massoud R; Chakhachiro Z; Mahfouz R; Nassif S; El-Cheikh J; Bazarbachi A; Abou Dalle I
    Leuk Res; 2021 Jun; 105():106568. PubMed ID: 33857784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.